We are live on ! Find out more
CPRX icon

Catalyst Pharmaceutical
CPRX

38 hedge funds and large institutions have $23.7M invested in Catalyst Pharmaceutical in 2014 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

160% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 5

150% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 4

100% more call options, than puts

Call options by funds: $8K | Put options by funds: $4K

31% more capital invested

Capital invested by funds: $18.1M → $23.7M (+$5.57M)

19% more funds holding

Funds holding: 32 → 38 (+6)

Holders
38
Holders Change
+6
Holders Change %
+18.75%
% of All Funds
1.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
13
Reduced
5
Closed
4
Calls
$8K
Puts
$4K
Net Calls
+$4K
Net Calls Change
-$5K

Top Buyers

1
BBA
Baker Bros. Advisors
New York
+$1.19M
2
SC
Sophrosyne Capital
New York
+$591K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$420K
4
WMSA
Weiss Multi-Strategy Advisers
New York
+$209K
5
AQR Capital Management
AQR Capital Management
Connecticut
+$108K

Top Sellers

1
ZIM
Zacks Investment Management
Illinois
-$303K
2
Jane Street
Jane Street
New York
-$83K
3
TRCT
Tower Research Capital (TRC)
New York
-$33.5K
4
Citadel Advisors
Citadel Advisors
Florida
-$24.8K
5
TAM
Telluride Asset Management
Minnesota
-$22K
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
1
Federated Hermes
Pennsylvania
$7.38M +$25.2K +12,040 +0.4%
O
2
OrbiMed
New York
$4.28M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$3.69M +$420K +200,742 +14%
OM
4
Opaleye Management
Massachusetts
$3.12M +$51.6K +24,684 +2%
BBA
5
Baker Bros. Advisors
New York
$1.29M +$1.19M +569,853 New
SC
6
Sophrosyne Capital
New York
$638K +$591K +282,500 New
AQR Capital Management
7
AQR Capital Management
Connecticut
$455K +$108K +51,600 +34%
GTC
8
Ghost Tree Capital
New York
$452K +$52.3K +25,000 +14%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$392K +$17.5K +8,370 +5%
TCM
10
Tanaka Capital Management
New York
$298K – – –
Bank of New York Mellon
11
Bank of New York Mellon
New York
$279K +$45.7K +21,874 +22%
WMSA
12
Weiss Multi-Strategy Advisers
New York
$226K +$209K +100,000 New
Northern Trust
13
Northern Trust
Illinois
$174K +$22.5K +10,743 +16%
Deutsche Bank
14
Deutsche Bank
Germany
$113K +$105K +50,000 New
State Street
15
State Street
Massachusetts
$107K – – –
Dimensional Fund Advisors
16
Dimensional Fund Advisors
Texas
$105K – – –
CPA
17
Cowen Prime Advisors
New York
$98K +$28.3K +13,550 +45%
California Public Employees Retirement System
18
California Public Employees Retirement System
California
$91K – – –
U
19
UBS
Switzerland
$74K +$68.1K +32,551 New
FANJ
20
Financial Architects (New Jersey)
New Jersey
$68K – – –
CAN
21
Cetera Advisor Networks
California
$54K -$8.36K -4,000 -14%
GC
22
Guggenheim Capital
Illinois
$44K +$9.28K +4,436 +29%
Bank of America
23
Bank of America
North Carolina
$40K +$8.47K +4,053 +30%
Group One Trading
24
Group One Trading
Illinois
$29K -$468 -224 -2%
RCM
25
Rotella Capital Management
Washington
$28K +$25.7K +12,300 New
1
2

CPRX Hedge Fund Activity: Q1 2014 in Review

38 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2014, worth a combined $23.7M — up 31% from $18.1M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new CPRX positions and 4 closed out — a net gain of 6 holders — while 13 added to existing stakes and 5 trimmed.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $1.19M. The largest seller was Zacks Investment Management, exiting entirely with an estimated $303K sold.

  • 38 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2014, up from 32 in Q4 2013.
  • Funds reported $23.7M of Catalyst Pharmaceutical stock for Q1 2014, up 31% quarter-over-quarter.
  • 10 funds opened new Catalyst Pharmaceutical positions in Q1 2014 and 4 closed out, a net change of +6 holders.
  • The largest Catalyst Pharmaceutical buyer in Q1 2014 was Baker Bros. Advisors, an estimated $1.19M added.
  • The largest Catalyst Pharmaceutical seller in Q1 2014 was Zacks Investment Management, an estimated $303K sold.

Based on aggregated 13F filings for Q1 2014.